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Fusion geneChronic granulomatous disease (CGD) is a rare congenital disorder in which phagocytes cannot generate super-
oxide (O2−) and othermicrobicidal oxidants due tomutations in one of theﬁve components of theO2−-generating
NADPH oxidase complex. The most common autosomal subtype of CGD is caused by mutations in NCF1,
encoding the NADPH subunit p47phox. Usually, these mutations are the result of unequal exchange of chro-
matid between NCF1 and one of its two pseudogenes. We have now investigated in detail the breakpoints
within or between these (pseudo) NCF1 genes in 43 families with p47phox-deﬁcient CGD by means of
multiplex ligase-dependent probe ampliﬁcation (MLPA). In 24 families the patients totally lacked NCF1
sequences, indicating that in these families the cross-over points are located between NCF1 and its
pseudogenes. Six other families were compound heterozygous for a total NCF1 deletion and another muta-
tion in NCF1 on the other allele. In 8 families, the patients lacked NCF1 exons 1–4 but had retained NCF1
exons 6–10, indicating that a cross-over point is located within NCF1 between exons 4 and 6. Similarly,
in 4 families a cross-over point was located within NCF1 between exons 2 and 4. Similar cross-overs, in het-
erozygous form, were observed in family members of the patients. Several patients were compound het-
erozygous for total and partial NCF1 deletions. Thus, at least three different cross-over points exist
within the NCF1 gene cluster, indicating that autosomal p47phox-deﬁcient CGD is genetically heteroge-
neous but can be dissected in detail by MLPA.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
1.1. Chronic granulomatous disease
Chronic granulomatous disease (CGD) is an inherited immunode-
ﬁciency syndrome with an incidence of approximately 1 in 250,000
newborns, without any ethnic prevalence. Patients with this disorder
usually have recurrent bouts of infection due to the decreased capac-
ity of their immune system to eliminate pathogenic microorganisms.
This disorder is generally manifested in childhood with recurrent, se-
vere infections [1].
CGD is caused by failure of phagocytes to intracellularly kill path-
ogens. Neutrophils, in particular, fail to produce superoxide ion radi-
cals (O2−) and their derivatives, which are needed to kill infectiouse; CYBB, Cytochrome b beta;
plex ligase-dependent probe
otein of 47kD; phox, phagocyte
pecies; SNP, single nucleotide
lood Cell Research, Plesmanlaan
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ion.
l rights reserved.microorganisms. At the site of an infection, neutrophils contact mi-
croorganisms or inﬂammatory mediators, which then activate the
NADPH oxidase enzyme complex. This enzyme complex is responsi-
ble for superoxide radical formation in these cells by transferring
electrons from NADPH inside the cell to molecular oxygen across
the cell membrane. The produced superoxide undergoes a series of
reactions to yield hydrogen peroxide, hydroxyl radicals and hypochlo-
rite. These Reactive Oxygen Species (ROS) produced by the phagocytes
collaborate with proteolytic enzymes (released from granular storage
compartments into the phagosome containing the ingested microor-
ganisms) in killing the microorganisms.
1.2. NADPH oxidase
In resting phagocytes, the NADPH oxidase enzyme is inactive, be-
cause its components are located in different cell compartments. One
component, ﬂavocytochrome b558, is composed of two subunits,
gp91phox and p22phox, and located in the plasma membrane and
membrane of the granules. Gp91phox is the enzymatic subunit of the
NADPH oxidase: it contains an NADPH-binding site, a FAD prosthetic
group and two heme groups. P22phox stabilizes the expression of
gp91phox in the membrane. Both correct localization of the NADPH
oxidase after activation and electron transfer within gp91phox are de-
pendent on interaction of gp91phox with a trimeric protein complex.
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p40phox, p47phox and p67phox. After cell activation by phagocytosis or
interaction with inﬂammatory mediators, the p40/p47/p67phox com-
plex moves to the phagosomal membrane and interacts with
gp91phox. This process is facilitated by a small GTPase (Rac2 in neutro-
phils). Assembly of this complex causes a conformational change in
gp91phox that enables NADPH to bind and donate electrons, thus
starting the enzymatic activity (Suppl. Fig. 1) [1,2].
1.3. Genetics of CGD
Defects in any of the essential subunits of the NADPH oxidase en-
zyme complex cause neutrophils to lose their bactericidal capacity,
and this in turn leads to CGD. There are several inherited forms of
CGD. The most frequent form of CGD is X-linked and is caused by a
defect in the gp91phox subunit, encoded by CYBB on the X chromo-
some. Mutations in the genes encoding p22phox, p67phox or p47phox
are inherited in an autosomal recessive form [3].
1.4. NCF1 and pseudogenes
The cytoplasmic p47phox subunit of the NADPH oxidase enzyme is
encoded by NCF1. This gene is located on chromosome 7 at location
11.23 and encodes a protein of 390 amino acids. The NCF1 gene is
15 kb long and consists of 11 exons varying from 55 to 165 bp in
length. In healthy individuals, the NCF1 gene locus contains one
NCF1 gene and two pseudo-NCF1 (Ψ-NCF1) genes, one on either
side of NCF1 [4–6]. The pseudogenes are >99% homologous to NCF1
but differ from NCF1 in one important aspect: they both contain a
GT deletion (ΔGT) at the start of exon 2, causing a frameshift and pre-
mature termination of protein synthesis. In addition, some single nu-
cleotide polymorphisms (SNPs) distinguish NCF1 from Ψ-NCF1 at
various locations [7]. These SNPs are used as segregation points to
distinguish NCF1 from its pseudogenes and can be used to analyze
DNA from CGD patients.
The mutations found in NCF1 in autosomal p47phox-deﬁcient
(A470) CGD patients are not as heterogeneous as those found in
other CGD subtypes. More than 90% of all A470 CGD patients lack an
intact NCF1 exon 2, meaning they only have Ψ-NCF1 exon 2 se-
quences, containing the GT deletion [8–10]. This is caused by unequal
cross-over events between NCF1 and Ψ-NCF1 during DNA replication
or repair [11,12]. In principle, this unequal cross-over can take place
between NCF1 and its pseudogenes (Fig. 1A) or within NCF1 and a
pseudogene (Fig. 1B). The ﬁrst mechanism results in the deletion of
NCF1 from one allele. A child inheriting such an allele from both of
its parents will suffer from a total deletion of NCF1 and thus from a
lack of p47phox. In the second mechanism, the result will be the for-
mation of a fusion gene, with one part derived from an NCF1
pseudogene and another part derived from the NCF1 gene. If the 5′
end of such a fusion gene is derived from a pseudogene, thus lacking
an intact exon 2, the fusion gene will not encode a functional protein
(Fig. 1B, allele 1). A child inheriting such alleles from both parents
will also be a p47phox-deﬁcient CGD patient. If the 5′ end of the fusion
gene is derived from NCF1, the fusion gene might encode a functional
p47phox protein [13] (Fig. 1B, allele 2), but we have obtained indica-
tions that in such situations the mRNA splicing is disturbed, again
disrupting production of functional p47phox (unpublished).
1.5. Goal of the present study
In the past, we have set up a method to measure the ratio between
the number of functional NCF1 exons 2 and pseudo-NCF1 exons 2
(with the GT deletion) [14]. In healthy individuals, this ratio is 1:2.
In p47phox patients, we often found no NCF1 exon 2 sequence at all
(except in patients with a different mutation in NCF1 [15]). In carriers
we found a 1:5 ratio, indicating that one allele had completely lost theNCF1 exon 2 sequence and gained the pseudogene sequence, while
the other allele had remained normal. However, this method does
not give insight into the unequal cross-over point in these families.
Therefore, the goal of the present study was to identify the different
unequal cross-over points between NCF1 and ψ-NCF1 in DNA samples
from A470 patients, carriers, and healthy individuals. As an appropri-
ate method to characterize A470-CGD we used MLPA (multiplex
ligation-dependent probe ampliﬁcation) [16].
2. Materials and methods
2.1. Blood, cells, DNA
Ethylenediaminetetraacetic acid (EDTA)-anticoagulated blood
from healthy individuals, CGD patients and their relatives was
obtained after appropriate informed consent had been obtained. Neu-
trophils were puriﬁed and tested for NADPH oxidase activity as previ-
ously described [15]. Western blotting was used to determine p47phox
expression; lack of expression indicated NCF1-related CGD [15]. The
mononuclear leukocyte fraction was used for DNA extraction. Geno-
mic DNA was isolated from whole blood with the Gentra Puregene
Kit (Qiagen, Hilden, Germany), according to the manufacturer's
instructions.
2.2. Gene scan for NCF1 GT deletion
Gene scan was used to determine the ratio between the number of
NCF1 exon 2 sequences and the number of Ψ-NCF1 exon 2 sequences.
This was performed according to Dekker et al. [14].
2.3. MLPA assay
Multiplex ligation-dependent probe ampliﬁcation (MLPA) is a
quantiﬁcation technique that determines gene copy numbers [16].
With probes that bind to the genetic region of interest, these regions
are ampliﬁed to determine the copy number present at this location.
The MLPA assay was performed with pre-packaged kits provided by
MRC Holland (Amsterdam, The Netherlands), which contained all
necessary reagents. Synthetic probes for NCF1 sequences were
designed by using NCF1-speciﬁc SNPs not present in pseudo-NCF1
[7]. Probes were obtained from Invitrogen (see complementary
table for probe sequences). Probes for exons 1 and 9 did not provide
reliable results, but were included in the experiments in order to sta-
bilize the assay. Results obtained with these probes are not included
in this report. Control probes annealing to other genomic regions
were also included in the analysis. These served to provide informa-
tion about the functionality of the assay and about the quality of the
DNA of the samples.
2.4. MLPA assay conditions
The concentration of DNA in the samples was adjusted to 20 ng/μl.
Each run contained no more than 32 samples, including four samples
from healthy individuals, which served as controls. Expanding the
total number of samples required one extra healthy control sample
for every seven experimental samples. MLPA reaction conditions
and constituents are found in protocols (www.mlpa.com).
2.5. Analysis of MLPA results
Results were analyzed with GeneMarker version 1.9, Soft Genet-
ics Software (LLC State College, PA, USA). This software required
the design of a panel in which the NCF1 probes and control probes
are deﬁned according to their size. Average panel settings used are
found in Table 1 (other panel settings not included). Note that
panel settings were reviewed and adjusted per run to optimize
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Fig. 1. A. Crossing over between NCF1 (allele 1, top) and one of its pseudogenes (allele 2, top), resulting in complete removal of functional NCF1 from one allele (allele 1, bottom)
and addition of NCF1 on the other allele (allele 2, bottom). B. Crossing over within NCF1 (allele 1, top) and one of its pseudogenes (allele 2, top), leading to the formation of fusion
genes. If the 5′ end of a fusion gene is derived from a pseudogene and lacks a functional exon 2, this fusion gene will not encode a functional protein.
Table 1
Size callings for probes as assigned by GeneMarker.
Size Left range Right range Allele name Control
87.5 0.5 0.5 Control 2 1
93.1 0.5 0.5 Exon 2 0
98.7 0.5 0.5 Control 3 1
103.1 0.5 0.5 Intron 1 0
107.9 0.5 0.5 Exon 1 0
112.4 0.5 0.5 Control 4 1
117.5 0.5 0.5 Exon 4 0
122.4 0.5 0.5 Intron 10 0
126.1 0.5 0.5 Control 5 1
134.6 0.5 0.5 Exon 7 0
149.0 0.5 0.5 Exon 6 0
162.6 0.5 0.5 Exon 9 0
171.6 0.5 0.5 Control 8 1
176.3 0.5 0.5 Control 9 1
205.2 0.5 0.5 Control 1 1
220.3 0.5 0.5 Control 10 1
1664 A. Hayrapetyan et al. / Biochimica et Biophysica Acta 1832 (2013) 1662–1672inclusion of all relevant peaks. Left and right ranges were kept at 0.5
during all analyses.
MLPA analysis by GeneMarker gave signals ranging from 0.00 to
2.50. These signals were based on the deviation from the signals
obtained with control samples, which gave an average score of 1.0.
In this way, the control samples served as a reference for the scores
of the patient samples, and therefore needed to be reviewed individ-
ually to conﬁrm that their signals fell into the 0.70–1.30 range. A
(control) sample was dismissed from further analysis if it showed ab-
errant signals for two or more of the control probes, in which a signal
between 0.70 and 1.30 (mean 1.0) was interpreted as a normal value.
Signals from other probes were interpreted as follows: 0.00–0.25
total lack of relevant NCF1 sequence (red color in Tables 2–5); 0.35–
0.75 1 copy of relevant NCF1 sequence (yellow color in Tables 2–5);
0.85–1.25 2 copies of relevant NCF1 sequence (green color in
Tables 2–5); 1.35–1.75 3 copies of the relevant NCF1 sequence (light
blue color in Tables 2–5); >1.85 4 copies of the relevant NCF1 se-
quence (dark blue color in Tables 3 and 4). Results that fell into the
gaps within these ranges were interpreted individually by comparing
Table 2
MLPA results for healthy donors.
Control number
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
DNA number
255
1133
2403
2421
2551
2622
2622
2637
2997
3075
3107
3193
3407
3682
3734
4007
Intron 1
0.71
1.02
1.01
1.01
0.99
1.00
1.05
1.00
0.98
0.99
1.08
0.97
1.00
0.98
0.99
1.16
Exon 2
1.18
0.99
1.00
1.30
0.93
0.96
1.01
1.02
0.97
0.96
1.01
0.95
0.97
1.08
1.10
0.94
Exon 4
1.08
1.75
0.99
1.28
1.08
0.90
0.96
0.98
1.00
1.01
0.96
0.52
0.50
1.00
1.07
1.01
Exon 6
0.99
1.02
0.97
0.98
1.23
1.00
0.98
0.97
0.99
0.95
0.98
0.97
1.04
1.00
1.00
1.09
Exon  7
1.00
0.99
0.99
0.94
1.08
0.92
0.97
0.98
1.00
0.97
0.97
0.99
0.98
1.05
1.21
0.98
Intron 10
1.04
1.07
0.98
0.94
1.08
0.91
0.93
1.01
1.06
0.98
0.99
0.93
0.99
0.98
1.13
0.96
17 4472 0.96 0.98 0.66 1.23 1.10 1.08
18 4664 0.76 1.02 0.96 0.96 0.98 1.02
19 4893 0.98 1.02 1.27 1.43 1.35 1.12
20 4902 1.00 1.01 1.04 1.05 1.03 0.55
21 5116 0.99 0.97 0.99 0.97 0.93 0.94
22 5304 0.86 1.09 1.02 1.07 1.08 1.03
23 5335 1.03 1.00 1.00 0.99 0.98 0.97
24 5456 0.73 0.89 0.74 1.27 1.17 0.94
25 5498 1.03 0.99 0.95 0.98 0.98 0.98
26 5717 0.98 1.03 1.03 1.24 1.06 1.01
27 5822 1.01 1.00 1.00 1.04 0.99 0.99
28 5911 0.98 0.94 0.89 0.97 0.97 0.93
29 6828 1.01 0.98 0.97 1.05 1.03 0.93
30 7027 0.96 1.00 0.96 1.03 0.99 0.99
31 7069 0.68 0.91 0.94 0.95 0.99 0.99
32 7273 0.98 1.11 0.96 0.95 1.00 0.99
33 7367 1.00 0.93 0.57 1.00 1.06 1.05
34 7711 1.00 0.95 0.98 1.04 0.98 0.56
35 7903 1.50 1.47 1.46 0.88 0.94 0.87
36 8019 1.42 1.55 1.09 0.98 0.91 0.91
37 8033 0.97 0.89 0.96 0.97 0.99 0.98
38 8082 1.01 0.93 0.97 0.97 0.90 1.03
39 8118 1.08 1.00 1.00 1.07 1.02 1.04
40 8121 1.01 0.90 0.98 0.95 0.95 0.92
41 8289 1.05 0.96 0.98 0.96 0.97 0.96
42 8480 0.84 1.05 0.99 1.02 0.98 1.01
43 8498 1.00 0.97 1.39 0.98 1.07 0.99
44 8578 0.97 0.94 1.02 1.05 0.93 0.95
45 8692 1.42 1.30 1.41 1.00 0.99 0.96
46 8757 1.01 1.01 0.92 0.99 0.93 1.21
47 8769 0.97 1.01 0.95 0.96 0.95 0.96
48 9428 1.03 0.92 0.80 0.92 0.89 0.98
49 9498 1.05 0.98 0.99 1.07 1.04 1.02
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bers after repeating the analysis of the sample.
3. Results
We analyzed DNA from 62 CGD patients in 43 families, and from
49 healthy donors. In all patients, the NADPH oxidase activity mea-
sured in neutrophils activated with phorbol myristate acetate in the
Amplex Red assay [17] was less than 5% of normal values (data not
shown). Western blot analysis showed total lack of p47phox expres-
sion in the patients' neutrophils (data not shown).
3.1. Healthy donors
All healthy donors had at least two copies of NCF1 at the exon 2
position, indicating that none of these donors are carriers of the GT
deletion (Table 2). In a few cases, a cross-over had taken place.
Healthy controls 19 and 36 showed a cross-over between exon 2
and exon 4, indicating that unequal exchange of chromatid had
taken place within NCF1 and ψ-NCF1, resulting in a gain of NCF1exon 2 copy numbers from 2 to 3. For healthy control 19, this gain oc-
curred after (3′ of) the cross-over in NCF1, whereas in control 36, this
gain occurred before (5′ of) the cross-over. Controls 35 and 45
showed a cross-over between exon 4 and exon 6, indicating that un-
equal exchange of chromatid had taken place within NCF1 and
ψ-NCF1, resulting in a gain of copy numbers of NCF1 sequences from
2 to 3 before (5′ of) the cross-over. Control 4 has a cross-over be-
tween exon 4 and exon 6 as well, also resulting in a gain of copy num-
bers of NCF1 sequences from 2 to 3 before (5′ of) the cross-over.
However, in this control the signal of intron 1 is lowered compared
to the signals of exon 2 and exon 4. Controls 1, 24 and 31 showed
also a lower copy number at intron 1, whereas controls 20 and 34
showed lower copy numbers at intron 10. Exon 4 proved to be quite
variable, with sporadic higher and lower copy numbers observable
in controls 2, 4, 12, 13, 17, 24, 33 and 43.
3.2. Patients
Using the gene scan method [14] we found that 53 of the 62 pa-
tients completely lacked the NCF1 exon 2 sequence (homozygous
Table 3
Crossover types in all studied CGD-NCF1 patients with homozygous ΔGT mutation (patients 1–53) and compound heterozygous ΔGT mutations (patients 54–61).
0.97
1.35
1.91
Patient number Family number DNA number Intron 1 Exon 2 Exon 4 Exon 6 Exon 7 Intron 10
1 1 361 0.00 0.00 0.00 0.08 0.06 0.00
2 2 2165 0.00 0.23 0.00 0.00 0.06 0.00
3 3 1462 0.00 0.08 0.00 0.07 0.08 0.00
4 4 497 0.00 0.00 0.06 0.06 0.09 0.00
5 5 494 0.00 0.00 0.00 0.00 0.00 0.00
6 6 880 0.00 0.00 0.00 0.08 0.07 0.00
7 7 1941 0.00 0.00 0.11 0.09 0.09 0.00
8 8 2333 0.00 0.22 0.10 0.09 0.08 0.00
9 9 1626 0.00 0.00 0.00 0.15 0.11 0.00
10 10 2162 0.00 0.00 0.00 0.00 0.00 0.00
11 10 2167 0.00 0.00 0.14 0.11 0.15 0.00
12 11 91 0.00 0.00 0.14 0.12 0.08 0.00
13 12 498 0.00 0.00 0.08 0.00 0.00 0.00
14 12 131 0.00 0.00 0.12 0.10 0.14 0.00
15 13 289 0.00 0.00 0.19 0.08 0.09 0.00
16 13 101 0.00 0.00 0.00 0.09 0.07 0.00
17 14 140 0 .00 0.00 0.00 0.11 0.08 0.00
18 14 19 0.00 0.00 0.00 0.12 0.10 0.00
19 15 2016 0.00 0.16 0.10 0.00 0.00 0.00
20 15 2015 0.00 0.00 0.00 0.00 0.06 0.00
21 16 1482 0.00 0.00 0.08 0.09 0.11 0.00
22 17 2364 0.10 0.18 0.08 0.05 0.04 0.00
23 17 2631 0.00 0.20 0.00 0.14 0.18 0.00
24 17 2663 0.00 0.12 0.10 0.16 0.11 0.00
25 18 1434 0.00 0.18 0.00 0.00 0.00 0.00
26 19 2335 0.00 0.00 0.10 0.09 0.06 0.00
27 19 2336 0.14 0.00 0.00 0.14 0.07 0.00
28 20 2430 0.17 0.00 0.15 0.19 0.14 0.00
29 20 2431 0.13 0.23 0.00 0.21 0.14 0.00
30 21 1611 0.00 0.15 0.00 0.05 0.09 0.58
31 22 1348 0.00 0.00 0.00
0.00
0.12 0.08
32 22 986 0.00 0.00 0.19 0.14 0.68
0.53
33 23 1615 0.00 0.00 0.00 1.04 0.98
34 23 1570 0.00 0.16 0.00 1.05 0.98 1.04
35 24 2405 0.00 0.00 0.00 0.96 1.06
36 25 2283 0.00 0.24 0.00 0.96 1.00 0.95
37 26 2025 1.08 0.00 0.00 0.98 0.97 0.92
38 27 788 0.00 0.17 0.00 1.16 1.17 1.13
39 28 141 0.00 0.00 0.00 0.40 0.47 0.48
40 29 1018 0.00 0.00 0.00 1.10 1.08 0.00
41 30 1507 0.00 0.00 0.00 0.50 0.56 1.05
42 30 1642 0.00 0.00 0.00 0.50 0.64 1.22
43 31 1560 0.00 0.18 0.93 1.18 0.87 0.95
44 31 1555 0.00 0.00 1.18 1.10 1.03 1.15
45 32 2166 0.00 0.00 0.66 0.56 0.65 0.66
46 32 2199 0.00 0.00 0.62 0.53 0.59 0.55
47 33 1653 0.00 0.00 0.64 0.57 0.59 0.00
48 34 2075 0.00 0.00 1.68 0.08 0.06 0.00
49 34 2078 0.00 0.00 1.79 0.15 0.13 0.16
50 35 499 0.00 0.00 1.66 0.00 0.00 0.00
51 36 133 0.00 0.00 1.05 0.17 1.10 0.00
52 36 114 0.00 0.00 1.71 0.27 0.00
53 37 1868 0.00 0.00 1.05 0.64 0.63 0.61
54 38 100 0.87 0.69 0.73 0.69 0.78 0.78
55 39 1004 0.56 0.54 0.50 0.50 0.51 0.91
56 39 1363 0.69 0.58 0.70 0.57 0.58 0.93
57 39 585 0.59 0.57 0.55 0.59 0.62 1.01
58 40 1476 0.63 0.61 0.50 0.58 0.53 0.58
59 40 1475 0.68 0.51 0.59 0.71 0.69 0.65
60 41 1907 0.56 0.57 0.60 0.67 0.66 0.65
61 42 881 0.56 0.57 0.61 0.60 0.70 0.69
62 43 1622 0.56 0.72 0.19 0.53 0.52 0.00
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(not shown). These last 9 patients carried another mutation in NCF1
on the other allele [15]. In all patients, whether homozygotes or com-
pound heterozygotes for the GT deletion in exon 2 of NCF1, we found
absence of p47phox expression, less than 5% of normal NADPH oxidase
activity in the neutrophils and equally severe clinical expression of
the disease [15]. In contrast, individuals who only carried the GTdeletion on one allele, such as parents from GT deletion homozygous
patients, had normal p47phox expression, normal NADPH oxidase ac-
tivity and no clinical symptoms.
The53 patients from37 familieswith the homozygous GTdeletion in
exon 2 were ﬁrst analyzed by MLPA (Table 3). In patients 1 through 29
we found that the patients lacked NCF1 sequences at all investigated lo-
cations, indicating that unequal exchange of chromatid has taken place
1667A. Hayrapetyan et al. / Biochimica et Biophysica Acta 1832 (2013) 1662–1672between NCF1 and one of its pseudogenes, as depicted in Fig. 1A. In pa-
tients 30–32 we found a similar result, except that the intron 10 probe
showed a positive signal on one allele. Since we were unable to design
an NCF1-speciﬁc probe 3′ of intron 10, we cannot distinguish betweenTable 4
CGD-NCF1 patients with homozygous ΔGT mutation and family members.
Family 10 DNA number Intron 1 E
Patient 1 2162 0.00
Patient 2 2167 0.00
Father 2164 0.59
Mother 2163 0.65
Family 11 DNA number Intron 1 E
Patient 91 0.00
Father 96 0.77
Mother 99 0.52
Sister 98 0.69
Sister 97 0.82
Brother 94 1.07
F amily member 95 0.58
Family member 92 0.75
Family member 93 0.72
Family 12 DNA number Intron 1 E
Patient 1 498 0.00
Patient 2 131 0.00
Family member 1497 1.28
Family 13 DNA number Intron 1 E
Patient 1 289 0.00
Patient 2 101 0.00
Father 108 0.61
Mother 109 0.68
Family member 106 0.62
Family member 105 0.59
Family member 110 0.57
Family member 111 1.09
Family 14 DNA number Intron 1 E
Patient 1 140 0.00
Patient 2 19 0.00
Family 15 DNA number Intron 1 E
Patient 1 2016 0.00
Patient 2 2015 0.00
Father 2018 0.61
Mother 2019 0.60
Family 16 DNA number Intron 1 E
Patient 1482 0.00
Family member 12 0.62
Family 17 DNA number Intron 1 E
Patient 1 2364 0.10
Patient 2 2361 0.00
Patient 3 2363 0.00
Sister 2362 0.64a cross-over between NCF1 and Ψ-NCF1 in this area and the presence
of a SNP in intron 10 of Ψ-NCF1 as the cause of this positive reaction.
In patients 33 through 42 we found that the patients lacked NCF1
sequences from intron 1 to exon 4, whereas their DNA containedxon 2 Exon 4 Exon 6 Exon 7 Intron 10
0.00 0.00 0.00 0.00 0.00
0.00 0.14 0.11 0.15 0.00
0.47 0.55 0.56 0.54 0.47
0.62 0.70 0.59 0.60 0.00
xon 2 Exon 4 Exon 6 Exon 7 Intron 10
0.00 0.14 0.12 0.08 0.00
0.58 0.49 0.55 0.54 0.55
0.40 0.30 0.57 0.31 0.36
0.63 0.49 0.62 0.54 0.64
0.63 0.53 0.59 0.58 0.62
0.99 0.99 1.10 1.00 0.93
0.71 0.56 0.64 0.69 0.73
0.52 0.49 0.57 0.55 0.54
0.49 0.44 0.52 0.48 0.45
xon 2 Exon 4 Exon 6 Exon 7 Intron 10
0.00 0.08 0.00 0 .00 0.00
0.00 0.12 0.10 0.14 0.00
1.10 1.15 1.13 1.44 1.13
xon 2 Exon 4 Exon 6 Exon 7 Intron 10
0.00 0.19 0.08 0.09 0.00
0.00 0.00 0.09 0.07 0.00
0.54 0.48 0.58 0.50 0.47
0.59 0.57 0.54 0.55 0.57
0.47 0.71 0.54 0.63 0.61
0.59 0.51 0.55 0.56 0.55
0.62 0.52 0.59 0.56 0.55
0.87 0.89 1.09 0.99 0.95
xon 2 Exon 4 Exon 6 Exon 7 Intron 10
0.00 0.00 0.11 0.08 0.00
0.00 0.00 0.12 0.10 0.00
xon 2 Ex on 4 Exon 6 Exon 7 Intron 10
0.16 0.10 0.00 0.00 0.00
0.00 0.00 0.00 0.06 0.00
0.64 0.60 0.47 0.62 0.54
0.58 0.59 0.63 0.65 0.68
xon 2 Ex on 4 Exon 6 Exon 7 Intron 10
0.00 0.08 0.09 0.11 0.00
0.56 0.53 0.54 0.62 0.52
xon 2 Exon 4 Exon 6 Exon 7 Intron 10
0.18 0.08 0.05 0.04 0.00
0.20 0.00 0.14 0.18 0.00
0.12 0.10 0.16 0.11 0.00
0.68 0.59 0.64 0.75 0.78
(continued on next page)
Table 4 (continued)
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cates that an unequal cross-over has taken place within NCF1 and
ψ-NCF1 between exon 4 and exon 6.
In patients 43 through 46 and in patient 53 we found that they
lacked NCF1 sequences in intron 1 and exon 2, but their DNA did con-
tain single or double copies of NCF1 exon 4 through intron 10. This in-
dicates that an unequal cross-over has taken place within NCF1 and
ψ-NCF1 between exon 2 and exon 4.
Patients 48, 49, 50 and 52 showed increased exon 4 expression,
which coincides with the increased exon 4 signals we found in the
control group.
3.3. Patients' family members
The patterns of inheritance were further investigated by analyzing
the family members of the patients (Table 4). Parents were not avail-
able for testing in all families. In families 10 through 18, the patients
completely lacked NCF1. This was reﬂected by the genotype of the
parents, who were all carriers of one allele with a total deletion ofNCF1 sequences. In families 11, 12, 13, 15, 16, 17 and 18, healthy
non-parental family members showed at least one functional exon 2
allele. These results support the notion that the MLPA probes we
used for this assay are in general speciﬁc for NCF1 and do not hybrid-
ize with ψ-NCF1 sequences.
In family 32, the father of the patient lacked allNCF1 sequences on one
allele, whereas themother carried a cross-over between exon 2 and exon
4 on one of her alleles. This indicates that the patients in this family are
compound heterozygotes of these two alleles. In family 25, the mother
lacked all NCF1 sequences on one allele, but the father must have a
more complicated genotype to explain the results in his son, who had
no NCF1 sequences in the 5′ part of NCF1 but two normal NCF1 alleles
in the 3′ part. This family is discussed in more detail in the Discussion.
Three families (31, 32, 33) showed a cross-over position between
exon 2 and exon 4, indicating that unequal exchange has taken place
within NCF1 and ψ-NCF1. No other family members were available for
testing in family 31. Family 33 shows that the father carries the total
deletion on one of his alleles and the mother the partial deletion, the
combination of which has led to the genotype of the patient.
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In the 9 patients from 6 families with a heterozygous GT deletion
in NCF1 exon 2 we identiﬁed other mutations in NCF1 on the allele
that carried the wild-type NCF1 exon 2 sequence [15] (Table 5).
Analysis by MLPA of the allele with the GT deletion revealed that
the patients in families 40–42 were heterozygotes for a total NCF1 de-
letion, whereas the patients in families 38, 39 and 43 showed varia-
tion in their copy numbers of the different sites in NCF1. In family
43, a deletion of exon 3–5 in the exon-2-containing allele caused a
total defect in exon 4 probe binding on both alleles.
3.5. Allele frequencies
In total, we determined the cross-over points in 72 alleles in the
ΔGT patients (families 1–37, with family 36 not interpretable). In ad-
dition, we analyzed families 38–43 with deletions on one allele. Of
these 78 alleles, 58 were total NCF1 deletions. In 15 alleles the
cross-over point occurred between exon 4 and exon 6, and 5 alleles
had a cross-over between exon 2 and exon 4. In 7 families, a deviant
copy number was noted at the intron 10 position (families 21, 22, 29,
30, 33, 39, 43). A similar deviant copy number was found at the intron
1 position in patient 3. In all cases of a single probe with aberrantTable 5
NCF1-CGD patients with heterozygous ΔGT mutation types and family members.
Family 38 DNA number Intron 1 Exon 2 Exon 4
Patient 100 0.87 0.69 0.73
Mother 102 1.01 1.05 0.96
Family 39 DNA number Intron 1 Exon 2 Exon 4
Patient 1 1004 0.56 0.54 0.50
Patient 2 1363 0.69 0.58 0.70
Patient 3 585 0.59 0.57 0.55
Father 1361 1.05 1.09 1.20
Mother 584 0.56 0.52 0.59
Family member 1014 0.54 0.51 0.53
Family member 1012 1.06 0.99 0.92
Family member 1008 0.89 0.92 1.19
Family member 1003 1.01 0.99 1.11
Family 40 DNA number Intron 1 Exon 2 Exon 4
Patient 1 1476 0.63 0.61 0.50
Patient 2 1475 0.68 0.51 0.59
Father 1484 0.75 0.62 0.74
Mother 1483 1.05 0. 93 1.12
Family 41 DNA n umber Intron 1 Exon 2 Exon 4
Patient 1907 0.55 0.43 0.53
Father 1909 0.54 0.49 0.54
Mother 1908 0.65 0.59 0.65
Family 42 DNA number Intron 1 Exon 2 Exon 4
Patient 881 0.56 0.57 0.61
Family 43 DNA number Intron 1 Exon 2 Exon 4
Patient 1622 0.56 0.72 0.19
Father 1.08 0.91 0.61
Mother 592 0.67 0.71 0.64
sister 593 0.79 0.93 0.55results (no adjacent aberrant sequences), we regarded this as a SNP
and did not count this as a cross-over. The allele frequency thus
came out at 74.4% total NCF1 deletions, 19.2% cross-overs between
exons 4 and 6, and 6.4% cross-overs between exons 2 and 4.
4. Discussion
In this study we have analyzed the different cross-over positions
in 62 p47phox-deﬁcient CGD patients, of which 53 had a homozygous
GT deletion in exon 2 of NCF1 — the most common causative muta-
tion for this subtype of CGD. In the other 9 patients, CGD was caused
by a combination of ΔGT in exon 2 on one allele and another mutation
elsewhere in NCF1 on the other allele. Crossing-over positions were
determined with the MLPA technology, which identiﬁes and quan-
tiﬁes regions of interest based on gene-speciﬁc probes.
4.1. Exon 4
Gene-speciﬁc probes were designed according to the known
segregating SNPs in NCF1 and its pseudogenes [7]. In general, this
method worked well, and we thus identiﬁed at least three different
unequal cross-over points between NCF1 and its pseudogenes in
CGD patients with a GT deletion in NCF1 exon 2. However, someExon 6 Exon 7 Intron 10 Mutation type
0.69 0.78 0.78 Unknown mutation
0.96 1.01 1.05 Carrier  not  ΔGT
Exon 6 Exon 7 Intron 10
0.50 0.51 0.91 ΔGT/c.333T>A [13, 16]
0.57 0.58 0.93 ΔGT/c.333T>A 
0.59 0.62 1.01 ΔGT/c.333T>A
1.02 1.10 0.72 Carrier c.333T>A 
0.70 0.58 1.15 Carrier ΔGT 
0.57 0.58 0.55 Carrier ΔGT
1.04 1.05 0.60
1.04 1.17 0.58
0.92 0.88 0.68
Exon 6 Exon 7 Intron 10
0.58 0.53 0.58 ΔGT/c.682+1G>C [16]
0.71 0.69 0.65 ΔGT/c.682+1G>C 
0.57 0.78 0.75 Carrier ΔGT 
0.86 1.00 0.82 Carrier c.862+1G>C 
Exon 6 Exon 7 Intron 10
0.52 0.52 0.53 ΔGT/c.838delC 
0.46 0.50 0.51 Carrier ΔGT 
0.57 0.68 0.65 Carrier c.838delC
Exon 6 Exon 7 Intron 10
0.60 0.7 0 0.69 ΔGT/353,354TC>AA[13, 16]
Exon 6 Exon 7 Intron 10
0.53 0.52 0.00 ΔGT/Δexon3-5
1.07 1.14 0.57 Carrier Δexon3-5
0.62 0.69 0.61 Carrier ΔGT
0.85 0.86 0.42 Carrier Δexon3-5
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and in the CGD patients, we found quite a large deviation from the
normal two copies of NCF1 exon 4. In 5 of 49 healthy controls, we
found only one copy of exon 4. Gene-speciﬁc sequencing revealed
that this was due to the presence of c.269A instead of the presumed
NCF1-speciﬁc c.269G in this exon. According to the SNP (c.269) used
to distinguish gene NCF1 exon 4 (nucleotide: G) from pseudogene
ψ-NCF1 exon 4 (nucleotide: A), the probe used for the MLPA was
designed to ligate only to the nucleotide speciﬁc for the gene (G).
However, in 5.6% of 120 other control samples both a G and an A
were noted with gene-speciﬁc sequencing, indicating that both G
and A can be found in NCF1 exon 4. Most likely, in cases where
more than two copies of only exon 4 were noted (such as in controls
2 and 43 and in patients 48–50 and 52) a G is present in one or two of
the pseudogene exons 4, to which the presumed gene-speciﬁc probe
was able to bind. This could not be veriﬁed experimentally, because it
is not very well possible to sequence ψ-NCF1 exons 4 independently
from NCF1 exon 4. If the outlying higher results found in patients 48
through 50 can be accounted to this probe binding to NCF1 as well
as to ψ-NCF1, these patients would all have a total deletion of NCF1.
This would expand the subgroup with a complete lack of NCF1 from
29 to 32 patients. For our calculation of the allele frequency of the dif-
ferent cross-overs, we have assumed that this is indeed the case.
4.2. Intron 10
Another problem is whether the deviant sequence copy numbers
found at the intron 10 position in 7 families are due to a cross-over
between exon 7 and intron 10 or to incorrect probe binding caused
by an underlying SNP. Attempts at designing a new NCF1-speciﬁc
probe for the intron 10 region or more downstream regions were
not successful and did not give further insight into the nature of the
unusual results. However, if these results are due to incorrect probe
binding caused by a SNP present within the family and there is no
normal NCF1 sequence present at the intron 10 position, patients
30, 31 and 32 would all have a complete NCF1 deletion, expanding
this subgroup from 32 to 35 patients. Similarly, patients 41 and 42
would then be heterozygotes for a complete NCF1 deletion. We
have assumed this to be true. Nonetheless, this remains a point that
requires further investigation to exclude the presence of yet another
cross-over point within NCF1.
4.3. Intron 1
In family 26, the patient shows a cross-over point between exon 4
and exon 6 within NCF1 and ψ-NCF1. However, this patient still shows
two NCF1 sequences at the intron 1 point. This coincides with the ge-
notypes of the parents: both parents show normal NCF1 intron 1 se-
quences. Here again, we cannot distinguish between an NCF1 SNP in
one of the ψ-NCF1 genes or a double cross-over within NCF1.
4.4. Exceptional families
Other exceptions include patient 35 (family 24), who, according to
the MLPA results, had 3 copies of NCF1 at the exon 6 position. This
ﬁnding is out of line with the deletion of NCF1 at all the upstream po-
sitions, and the double copies of NCF1 found at the downstream posi-
tions. Patient 37 (family 26) showed a double copy of NCF1 at the
intron 1 position — the only case in the entire group of patients.
This can be due to a SNP causing aberrant probe binding to
pseudogenes or to a double cross-over within NCF1.
In family 25, the father probably carries one allele (#1) with nor-
mal NCF1 sequences except a polymorphism that prevents binding of
the probe in intron 10 (see his daughter), and another allele (#2)
with two fusion genes with the 5′ part of ψ-NCF1 and the 3′ part of
NCF1, the cross-over being between exon 4 and exon 6. On thissecond allele the father thus has zero NCF1-speciﬁc sequences in in-
tron 1, exon 2 and exon 4 and two NCF1-speciﬁc sequences in exon
6, exon 7 and intron 10. Together this leads in the father to one
NCF1 sequence in intron 1, exon 2 and exon 4, three NCF1 sequences
in exons 6 and 7 and two NCF1 sequences in intron 10. The mother
had one allele (#1) with only ψ-NCF1 sequences and another allele
(#2) with one normal NCF1 gene. Their affected child has then
inherited his father's allele #1 and his mother's allele #1, and his sis-
ter her father's allele #2 and her mother's allele #1.
4.5. Allele frequencies
Lastly, the allele frequencies were determined per family. In fam-
ilies with more than one patient, the allele frequency was counted
only once. The afore-mentioned exceptional samples have been cate-
gorized into the different cross-over groups, assuming that the devi-
ant results can be attributed to aberrant probe binding. Clearly, the
most abundant cause of GT deletion in exon 2 of NCF1 is unequal
cross-over of NCF1 and its pseudogenes at positions in between
these genes, leading to a complete lack of NCF1 sequences. However,
it must be realized that further heterogeneity in this category is pos-
sible, with different sites of actual chromatid exchange. At least two
exchange sites were identiﬁed inside NCF1, i.e. between exons 2 and
4 and between exons 4 and 6. Possibly, additional exchange sites
within NCF1 also exist, e.g. between intron 1 and exon 2 and between
exon 7 and intron 10.
4.6. Origin of the cross-over events
The highly homologous (>99%) nature of NCF1 and its ψ-NCF1
counterparts allows for cross-over events to occur at many positions
throughout the gene. Alu repeat elements, which are known to pro-
vide abundant cross-over opportunities [18], are present in NCF1 in
introns 1, 2, 5, 7 and 8 [4]. Those in introns 2 and 5 might therefore
be involved in the cross-overs we found between exons 2 and 4 and
between exons 4 and 6, respectively. We recently found that the
exons 3–5 deletion in family 43 is caused by unequal cross-over with-
in NCF1 between Alu repeats in intron 2 and in intron 5 [19]. There are
also three GT repeats present in exons 2, 8 and 11. However, as these
are very short repeats ([GT]n = 2), it is unlikely that these are causa-
tive for the cross-over events. In addition, the positions of these re-
peats are not found at the same positions as the cross-overs
identiﬁed by us.
4.7. Copy number variation and fusion genes
Recently, Brunson et al. [20] reported about copy number varia-
tion in human NCF1 and NCF1 pseudogenes in populations from dif-
ferent racial background. However, these authors distinguished the
three NCF1 (pseudo)genes only by the GT repeat in exon 2 and by a
1-bp difference in exon 9 between the two pseudogenes. Thus, the
possibility of fusion gene formation or SNP variation within the
three NCF1 genes, as we report here, was not taken into consider-
ation. Similarly, the idea of Heyworth et al. [13] that pseudogenes
may exist with the normal GTGT sequence in exon 2, also reported
by Brunson et al. [20], can easily be explained by the existence of fu-
sion genes. Whether such GTGT-containing fusion genes are actively
transcribed and translated as functional proteins in vivo remains to
be established. Our preliminary data indicate that such mRNA is un-
stable or not correctly spliced.
Splicing of NCF1 pseudogene mRNA is disturbed (see e.g. Ensembl
data base clones ENST00000574052 and ENST00000570911 or NCBI
data base clone NM_000285). It is to be expected that mRNA from fu-
sion genes will also be spliced incorrectly, and this was indeed found
by us. The problem lies in the 3′ part of the pseudogene; thus, we
found normal splicing of fusion gene mRNA with the 5′ part of a
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tient). However, we found abnormal splicing of mRNA with the 5′
part of NCF1 and the 3′ part of a pseudogene in a healthy donor
with a 1:1 ratio of NCF1 exon 2: pseudogene exon 2 (also 11 clones).
The cDNA PCR product of this donor showed a mixture of correctly
and incorrectly spliced mRNA in a PCR with an NCF1-speciﬁc primer.
When using a ΔGT-speciﬁc primer in the PCR, we found only incor-
rectly spliced mRNA. Presumably, this donor had 2 NCF1 genes, 3
pseudogenes and one fusion gene with 5′NCF1 sequences and 3′
pseudogene sequences, which correlate with the results found by
MLPA for this donor. In addition, we have found by MLPA in four
normal donors with a 1:1 ratio of NCF1 exon 2:pseudogene exon 2
that they all had a fusion gene with 5′NCF1 and 3′pseudogene se-
quences. Finally, we found similar fusion genes in all four members
of a family with a 2:1 ratio of NCF1 exon 2:pseudogene exon 2. In
our opinion, this invalidates the notion that such fusion genes may
have functional relevance, but more detailed investigations are re-
quired for deﬁnite conclusions.
5. Conclusion
In conclusion, we have shown that at least three different cross-
over points exist within the NCF1 gene cluster, indicating that autosomal
p47phox-deﬁcient CGD is genetically heterogeneous but can be dissected
in detail by MLPA.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.bbadis.2013.05.001.
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